Page 271 - ebook HCC

PROGRAMME AND ABSTRACTSAND ABSTRACTS
268 PROGRAMME GENEVA, SWITZERLAND EASL HCC SUMMIT 269
268
FEBRUARY 13 - 16, 2014

Poster Board Number C47

CURATIVE TREATMENT IN THE MANAGEMENT NOTES
OF SMALL HEPATOCELLULAR CARCINOMA

Rania Hefaiedh, Hayfa Romdhane , Nour Elleuch ,
1
1
Rym Ennaifer , Houda Ben Nejma , Najet Bel Hadj 1
1
1
1 Hepatology and Gastroenterology, Mongi Slim University Hospital, La Marsa, Tunisia
Corresponding author’s e-mail: rania.hefaiedh@hotmail.com
Introduction: Hepatocellular carcinoma is the first liver tumor worldwide. Therefore, it is a
matter of debate whether surgical treatment (hepatic resection) or percutaneous treatment
(radiofrequency ablation or alcoholic injection) should be preferred for the treatment of
patients with small hepatocellular carcinoma.
Aims: The aim of our study was to compare the long-term outcome and the survival
between surgically and percutaneously treated small hepatocellular carcinomas.
Methodology: A non-randomized comparative retrospective study was performed in the
department of hepatology of Mongi Slim hospital during a period of three years. The study
included all patients carrying a small hepatocellular carcinoma (according to Milan criteria)
which were divided into two groups: group 1 including patients who underwent surgical
treatment, and group 2 including patients who underwent percutaneous treatment. Patients
with a follow up lower than 6 months were excluded from the study. The cumulative
disease-free and overall survival between the two groups was compared.

Results: Among the sixty three patients who were diagnosed for hepatocellular carcinoma,
twenty eight carried a small hepatocellular carcinoma with a mean age of 63 years and sex
CLINICAL POSTER ABSTRACTS based on radiofrequency ablation in 9 cases (69%) and alcoholic injection in 4 cases CLINICAL POSTER ABSTRACTS
ratio of 0.64. Etiology of cirrhosis was post viral in 96%. Hepatic resection was performed
in 15 cases (53.5%) while percutaneous treatment was proposed for 13 cases (46.5%)
(31%). Overall survival was significantly lower in the surgical resection group than in the
percutaneous treatment group. The corresponding 6 months and 1 year overall survival
rates for the surgical resection group and the percutaneous treatment group were 100%,
100%, 20%, and 52%, respectively (p=0,04). The disease free survival for percutaneous
treatment and surgical resection were not significantly different.
Conclusion: Our results showed the efficacy and safety of percutaneous ablation
treatments (radiofrequency ablation or alcohol injection) which were better than those
of surgical treatment (hepatic resection) in patients with small hepatocellular carcinoma.
Percutaneous treatments had the advantages over surgical resection in being less
invasive and having lower morbidity.